Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Advances review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://lechj092dfe8.dreamyblogs.com/profile